%0 Journal Article %T B-cell malignancies and COVID-19: a narrative review %+ CHU Pontchaillou [Rennes] %+ Université de Rennes (UR) %+ Hospices Civils de Lyon (HCL) %+ Université Claude Bernard Lyon 1 (UCBL) %+ Centre International de Recherche en Infectiologie (CIRI) %A Luque-Paz, David %A Sesques, Pierre %A Wallet, Florent %A Bachy, Emmanuel %A Ader, Florence %< avec comité de lecture %@ 1198-743X %J Clinical Microbiology and Infection %I Elsevier for the European Society of Clinical Microbiology and Infectious Diseases %8 2023 %D 2023 %R 10.1016/j.cmi.2022.10.030 %M 36336236 %K B-cell depletion %K B-cell malignancies %K COVID-19 %K Convalescent plasma therapy %K Direct-active antiviral %K Neutralizing monoclonal antibody %K SARS-CoV-2 %K mRNA vaccine %K neutralizing monoclonal antibody %K convalescent plasma therapy %Z Life Sciences [q-bio]/CancerJournal articles %X Background. COVID-19 has been extensively characterized in immunocompetent hosts and to a lesser extent in immunocompromised populations. Among the latter, patients treated for Bcell malignancies have immunosuppression generated by B-cell lymphodepletion/aplasia resulting in a higher susceptibility to respiratory virus infections and poor response to vaccination. The consequence is that these patients are likely to develop severe or critical COVID-19. Objectives. To examine the overall impact of COVID-19 in patients treated for a B-cell malignancy or receiving chimeric antigen receptor T (CAR-T) immunotherapy administered in case of relapsed or refractory disease. Sources. We searched in the Medline database to identify relevant studies, trials, reviews, or meta-analyses focusing on SARS-CoV-2 vaccination or COVID-19 management in patients treated for a B-cell malignancy or recipients of CART cell therapy up to July 8 th , 2022. Content. The epidemiology and the outcomes of COVID-19 in B-cell malignancy patients and CART cell recipients are summarized. Vaccine efficacy in these subgroups is compiled. Considering the successive surges of variants of concern, we propose a critical appraisal of treatment strategies by discussing the use of neutralizing monoclonal antibodies, convalescent plasma therapy, direct-acting antiviral drugs, corticosteroids and immunomodulators. Implications. For B-cell malignancy patients, preventive vaccination against SARS-CoV-2 remain essential and management of COVID-19 includes the control of viral replication due to protracted SARS-CoV-2 shedding. Passive immunotherapy (monoclonal neutralizing antibody therapy, convalescent plasma therapy) and direct-active antivirals such as remdesivir and nirmatrelvir/ritonavir are the best currently available treatments. Real-world data and subgroup analyses in larger trials are warranted to assess COVID-19 therapeutics in B-cell depleted populations. %G English %2 https://hal.science/hal-03955801/document %2 https://hal.science/hal-03955801/file/Luque-Paz%20et%20al.%20-%202022%20-%20B-cell%20malignancies%20and%20COVID-19%20a%20narrative%20revi.pdf %L hal-03955801 %U https://hal.science/hal-03955801 %~ UNIV-ST-ETIENNE %~ ENS-LYON %~ HCL %~ UNIV-RENNES1 %~ CNRS %~ UNIV-LYON1 %~ HL %~ STATS-UR1 %~ UR1-HAL %~ TEST-UR-CSS %~ UNIV-RENNES %~ CIRI %~ UDL %~ UNIV-LYON